Sige Gutman, Life Sciences Litigation Practice Chair, shared insights with IAM in an article about a decision by the US District Court for the District of Delaware which found that a gene therapy patent of RegenxBio and the Trustees of the University of Pennsylvania was ineligible and granted summary judgement in favor of Sarepta Therapeutics.  
 
Sige points out that the ruling is significant for the development of many drug therapies because, "in the life sciences space, the development of the technology is far faster than the application of existing law." 

Source

IAM